MBX Share Price Performance

MBX Community Fair Values

View all narratives

Recent MBX News & Updates

No updates

Microbix Biosystems Inc. Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

n/a

Earnings per share (EPS): 0.011
Gross Margin: 57.74%
Net Profit Margin: 6.89%
Debt/Equity Ratio: 15.2%

View full report ›

Microbix Biosystems Inc. Competitors

About MBX

Founded: 1988
Employees: n/a
CEO: Cameron Groome
WebsiteView website: www.microbix.com

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Canadian Market Performance

0.7%

12.5%

17.7%

9.8%

Over the last 7 days, the market has remained flat, although notably the Healthcare sector declined by 4.0%. Meanwhile, the market is actually up 18% over the past year. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›

Microbix Biosystems Stock Price

MBX Share Price Performance

MBX Community Fair Values

Recent MBX News & Updates

Microbix Biosystems Inc. Key Details

Microbix Biosystems Inc. Competitors

Sanu Gold

Treviso Capital

Voice Mobility International

Veteran Capital

Riverwalk Acquisition

Canna 8 Investment Trust

Pentagon I Capital

Pardus Ventures

🇪🇺 🇬🇧 Momentum Is Returning to European and UK Markets

The Big Beautiful Deficit